The AI Saving Time and Lives

Yiannis Kiachopoulos is yet another Greek founder that was ahead of the AI hype. Today, with 12 of the 20 biggest pharma giants relying on his platform, Causaly, Yiannis's vision is at the root of life-saving research.

Every great idea starts with a simple "what if?" For Yiannis and his co-founder Artur, it was about teaching a computer to read like The Flash. Being computer scientists and bookworms, the pair dreamt of extracting knowledge at superhuman speeds. They zeroed in on the biomedical domain, a field bursting with millions of publications and crucial to human health. And there they had it: an AI-driven platform that could sift through these vast data troves in seconds, squeezing weeks of research into a mere coffee break.

Fast forward to today, and Causaly is on fire! With a whopping $60 million in Series B funding, the platform is set to redefine the future of drug discovery. The journey of drug development, often spanning over a decade, is being supercharged by Causaly's AI, which helps make sense of the intricate web of disease biology. The platform's hybrid approach, blending a top-tier knowledge graph with cutting-edge generative AI, is empowering researchers to make novel discoveries with a tenfold boost in productivity.

Causaly is co-founded by Yiannis Kiachopoulos and Artur Saudabayev who have cumulative, in-depth, international experience across consulting, computer science and natural language processing, truly understanding multiple dimensions of what it takes to build a strong company and product. It is no luck that the company is growing rapidly and is trusted by top investors and companies world-wide. With over 80 million unique interactions between entities on the platform, Causaly shows great promise for the future.